Adicet Bio director Andrew Sinclair resigns from board
Michael Grissinger takes over Sinclair's audit committee seat and becomes chair of the nominating and governance committee.
SEC filing
3 stories
Michael Grissinger takes over Sinclair's audit committee seat and becomes chair of the nominating and governance committee.
SEC filing
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
The company said 54% of evaluable patients hit DORIS remission at 12 months and plans to begin pivotal lupus nephritis trial start-up activities in the fourth quarter of 2026.
SEC filing